Drugs / SPD465
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT00202605 | Sep 2005 → Jan 2006 | attention deficit-hyperactivity disorder | Shire | Completed | Met primary |
| Phase 2 | NCT00928148 | Jun → Nov 2004 | attention deficit-hyperactivity disorder | Shire | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT00458445 | Apr → Jun 2007 | attention deficit-hyperactivity disorder | Shire | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00152022 | Apr → Nov 2005 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT00152035 | Mar 2005 → Nov 2006 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPD465 | “evaluating the use of the triple-bead mixed amphetamine salt (MAS) SPD465 as stimulant pharmacotherapy for ADHD.” PMID 20861587 ↗ Sep 20104“Safety and Efficacy of SPD465 in Adults With ADHD” NCT00202605 ↗ “Safety of SPD465 in Treating Adults With ADHD.” NCT00152035 ↗ |